David Kirn - Jan 23, 2024 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)

Role: Chief Executive Officer, Director
Signature: By: /s/ Scott Bizily as Attorney-in-fact David Kirn
Stock symbol: FDMT
Transactions as of: Jan 23, 2024
Transactions value $: -$104,851
Form type: 4
Date filed: 1/25/2024, 04:59 PM
Previous filing: Jan 8, 2024
Next filing: Feb 12, 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	FDMT	Common Stock	Sale	-$105K	-5.7K	-0.49%	$18.41	1.15M	Jan 23, 2024	Direct	F1, F2

Showing 1 to 1 of 1 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 17, 2023.
F2	The transaction was executed in multiple trades in prices ranging from $18.06 to $18.76, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Content

Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 17, 2023.

The transaction was executed in multiple trades in prices ranging from $18.06 to $18.76, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.